Budget Impact of Antidiabetic Formulary Changes

项目摘要 本论文研究的长期目标是帮助公共和私人支付者建立 他们自己的预算影响模型，以便更好地为他们的公式化决策提供信息，并最终 最大限度地提高其医疗保健系统的效率。我们将通过与以下合作实现这一目标 国家特里卡雷支付者，服务于军队及其家属，以开发一种 预算影响模型，用于其最近的公式变化。 这项研究的目的是评估TRICARE最近的抗糖尿病药物的预算影响 药品处方的变化。该项目的具体目标是：i)开发一个模型来预测 TICARE抗糖尿病药物处方变化对预算的影响，II)计算实际 实施公式更改后一年的经验预算影响，以及三) 识别、比较和对比预算影响模型中的成本动因与经验成本动因 分析。预算影响模型和经验分析都将使用现有的TRICARE 药房和医疗索赔数据。 为了成功地进行这项研究，首席调查员将参加国际协会 关于药物经济学和结果研究的短期课程，主题包括 预算影响分析、建模、高级决策建模和统计方法 经济评估，以及马里兰大学巴尔的摩分校的专业发展 研讨会和负责任地开展研究课程。首席调查员还将 作为患者计划的项目经理，学习利益相关者的参与。另外， 首席调查员将举行两周一次的一对一会议和两周一次的团队会议 赞助商-马里兰大学，巴尔的摩的穆林斯教授，他在预算方面有专长 影响分析和付款人参与，并将加强原则。除了赞助商， 其他四位专家在TRICARE，临床糖尿病治疗和管理，决策分析， 大型数据库将用于首席研究员的论文委员会，并提供 指导。

Project Summary The long-term goal of this dissertation research study is to help public and private payers build their own budget impact models, to better inform their formulary decisions, and ultimately maximize efficiency in their health care systems. We will achieve this goal by collaborating with the national TRICARE payer, which serves the military and their dependents, to develop a budget impact model for their recent formulary changes. The objective of this study is to evaluate the budget impact of TRICARE’s recent antidiabetic drug formulary changes. The specific aims of the project are: i) develop a model to predict the budgetary impact of TRICARE’s antidiabetic drug formulary changes, ii) calculate the actual empirical budget impact one year after implementation of the formulary changes, and iii) identify, compare, and contrast the cost drivers in the budget impact model versus empirical analysis. Both the budget impact model and empirical analysis will use existing TRICARE pharmacy and medical claims data. To successfully conduct this research, the principal investigator will attend International Society for Pharmacoeconomics and Outcomes Research short-course programs in topics such as budget impact analyses, modeling, advanced decision modeling, and statistical methods in economic evaluations, as well as University of Maryland, Baltimore professional development workshops and responsible conduct of research courses. The principal investigator will also learn stakeholder engagement as a project manager in the PATIENTS Program. Additionally, the principal investigator will have biweekly 1-on-1 meetings and biweekly team meetings with the sponsor-- University of Maryland, Baltimore’s Professor Mullins, who has expertise in budget impact analyses and payer engagement, and will reinforce principles. In addition to the sponsor, four other experts in TRICARE, clinical diabetes treatment and management, decision analyses, and large databases will serve on the principal investigator’s dissertation committee and provide guidance.